PhaseBio Pharmaceuticals phasebio.com


Public list: Smart Money VCs (6326) Pharma Startups (6570) Rare Diseases (230)

PhaseBio Pharmaceuticals (PHAS) is a clinical-stage biopharmaceutical company developing drugs to treat diabetes and cardiovascular dysfunction in patients suffering from rare diseases. The Company's discovery platform technology uses recombinant ELP biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. The resulting compounds are tuned for a specific rate of absorption, thereby increasing efficacy and reducing side effects.

PhaseBio Pharmaceuticals (PHAS) is a clinical-stage biopharmaceutical company developing drugs to treat diabetes and cardiovascular dysfunction in patients suffering from rare diseases. The Company's discovery platform technology uses recombinant ELP...Show all

Company (IPO / Went public)

Phone: 610-981-6500

Fax:

1 Great Valley Parkway
Suite 30
Malvern, 19355
Pennsylvania, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
PhaseBio Pharmaceuticals $144.9M Oct 18, 2018
See all 17 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related PhaseBio Pharmaceuticals Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 13 investors

Competitors

Company Status Description Investors

Biodel

Danbury, Connecticut, United States
IPO / Went publicBiodel Inc. is a biopharmaceutical drug delivery company. Biodel develops drug delivery technologies that increase drug efficacy, enhance drug performance, and make drugs easier for patients to take. This technology is applicable to a wide range of peptides, proteins and other macromolecules. Using this technology, Biodel has developed a drug formulation of recombinant human insulin designed to speed the delivery of insulin into the blood called ViajectTM to treat patients with Type 1 and Type 2...Show allLogin to see details

Catalyst Biosciences

South San Francisco, California, United States
MergedCatalyst Biosciences is developing next generation biopharmaceuticals by harnessing the catalytic power of engineered proteases that target proteins underlying diseases. Catalyst's discovery platform rapidly creates and optimizes tailor-made protease drug candidates that cleave a wide variety of disease targets, either by improving existing protease drugs or by creating new protease drugs, known as Alterase therapeutics. Catalyst is focusing its product development efforts on drug candidates for...Show allLogin to see details
See all 17 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)
Method for administering a sustained release formulation Nov 18, 2016 Mar 20, 2018 Patent
Modified vasoactive intestinal peptides Apr 08, 2015 Jul 11, 2017 Patent
Use of modified vasoactive intestinal peptides in the treatment of hypertension Jun 06, 2012 Feb 07, 2017 Patent
Modified vasoactive intestinal peptides Aug 16, 2010 May 12, 2015 Patent
Multimeric elp fusion constructs Jan 04, 2007 May 04, 2010 Patent
See all 15 patents